HDT Bio Receives $1 Million Award from BLUE KNIGHT™ Resident QuickFire Challenge in Support of Project NextGen

Oct 4, 2023 | Press Releases

Award will fund the development of HDT-201, HDT Bio’s thermo-stable and broad-spectrum intranasal RIG-I Agonist RNA SARS-CoV-2 antiviral candidate HDT-201 investigated as pre-exposure or post exposure prophylactic in high-risk situations SEATTLE, Oct. 4, 2023...

HDT Bio Announces Appointment of Key Clinical Oncology Experts

Sep 19, 2023 | Press Releases

Scientific Advisors to provide expertise and counsel on the clinical development of its RNA-based oncology pipeline candidates HDT Bio announces esteemed medical experts Dr. Charles Cobbs of the Swedish Neuroscience Institute and Dr. Elizabeth Jaffee of Johns Hopkins...

HDT Bio Publishes Peer-Reviewed Study Demonstrating Advantages of repRNA and LION™ Technology

Jul 24, 2023 | Press Releases

LION™-formulated repRNA vaccination exhibited a significant safety profile, along with enhanced efficacy and biodistribution response when compared to lipid nanoparticle (LNP)-formulated repRNA vaccines in mice Study findings, published in the peer-reviewed...

HDT Bio Publishes Peer-Reviewed Preclinical Study Demonstrating Robust Immunological Response in Mothers and Newborns Following repRNA/LION™ Vaccination

Mar 24, 2023 | Press Releases

LION-formulated, repRNA vaccination against HIV-1 and ZIKV successfully produced a robust immunological response in pregnant rabbits; maternal antibodies were transferred in utero to newborn kits Findings published in the peer-reviewed journal Molecular Therapy...

HDT Bio to Develop RNA Cancer Vaccines and Treatments with South Africa’s Pan African Cancer Research Institute (PACRI)

Jan 30, 2023 | Press Releases

Goal ‘to change the cancer research narrative in Africa’ by applying HDT Bio’s advanced technology to help reduce inequalities in health care PRETORIA, SOUTH AFRICA and SEATTLE, WA (January 30, 2023) – HDT Bio Corp., a developer of immunotherapies for infectious...

UTMB and HDT Bio awarded prototype project funding worth up to $87.4M from the U.S. government to develop saRNA vaccine technology

Nov 30, 2022 | Press Releases

UTMB will collaborate with HDT Bio Corp. and the National Institute of Allergy and Infectious Diseases’ Rocky Mountain Labs to develop vaccines against Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV) The 5-year $59M prototype project will develop...